Shares of biotech company CureVac N.V. (CVAC) were in the spotlight on Thursday after the company’s fourth-quarter revenue ...

The market has climbed by 5.8% over the past week, and is up 4.8% over the past year, with earnings expected to grow by 14% per annum in the coming years. Though the term 'penny stock' might sound ...

Q4 2024 Earnings Call Transcript April 10, 2025 CureVac N.V. misses on earnings expectations. Reported EPS is $-0.16564 EPS, ...

Strategic Milestone Achievement and Increased Financial Discipline Underscore Year of Corporate Transformation Completed ...

CureVac (CVAC) has reported its fourth quarter 2024 financial results, generating mixed reactions from investors as the company balances ...

CureVac (CVAC) announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for a Phase 1 clinical ...

Analysts estimate that CureVac will report an earnings per share (EPS) of $-0.09. Investors in CureVac are eagerly awaiting ...

The live webcast link can be accessed via the newsroom section of the CureVac website at https://www.curevac.com/en/newsroom/events/ Corresponding presentation slides ...

Pfizer, BioNTech win bid to invalidate CureVac's UK COVID vaccine patents Pfizer and its German partner BioNTech on Tuesday won their attempt to invalidate two of rival CureVac's patents at London ...

Curevac NV announced that the FDA has cleared its IND application for a phase I clinical study of CVHNLC in patients with ...

Commenting on the quarter Dr. Alexander Zehnder, Chief Executive Officer of CureVac said: "The fourth quarter of 2024 marked a strong finish to a year of significant transformation for CureVac.

Greetings. Welcome to CureVac Fourth Quarter and Full Year 2024 Financial Results and Business Update Call. At this time, all participants are in a listen-only mode. A question-and-answer session ...